tbuckley/cabot-search huggingface dataset:
Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics
Authors: Laurent Dercle, Matthew Fronheiser, Lin Lu, Shuyan Du, Wendy Hayes, David K. Leung, Amit Roy, Julia Wilkerson, Pingzhen Guo, Antonio T. Fojo, Lawrence H. Schwartz, Binsheng Zhao
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Using standard-of-care CT images obtained from patients with a diagnosis of non–small cell lung cancer (NSCLC), we defined radiomics signatures predicting the sensitivity of tumors to nivolumab, docetaxel, and gefitinib. Experimental Design: Data were collected prospectively and analyzed retrospectively across multicenter clinical trials [nivolumab, n = 92, CheckMate017 (NCT01642004), CheckMate063 (NCT01721759); docetaxel, n = 50, CheckMate017; gefitinib, n = 46, (NCT00588445)]. Patients were randomized to training or validation cohorts using either a 4:1 ratio (nivolumab: 72T:20V) or a 2:1 ratio (docetaxel: 32T:18V; gefitinib: 31T:15V) to ensure an adequate sample size in the validation set. Radiomics signatures were derived from quantitative analysis of early tumor changes from baseline to first on-treatment assessment. For each patient, 1,160 radiomics features were extracted from the largest measurable lung lesion. Tumors were classified as treatment sensitive or insensitive; reference standard was median progression-free survival (NCT01642004, NCT01721759) or surgery (NCT00588445). Machine learning was implemented to select up to four features to develop a radiomics signature in the training datasets and applied to each patient in the validation datasets to classify treatment sensitivity. Results: The radiomics signatures predicted treatment sensitivity in the validation dataset of each study group with AUC (95 confidence interval): nivolumab, 0.77 (0.55–1.00); docetaxel, 0.67 (0.37–0.96); and gefitinib, 0.82 (0.53–0.97). Using serial radiographic measurements, the magnitude of exponential increase in signature features deciphering tumor volume, invasion of tumor boundaries, or tumor spatial heterogeneity was associated with shorter overall survival. Conclusions: Radiomics signatures predicted tumor sensitivity to treatment in patients with NSCLC, offering an approach that could enhance clinical decision-making to continue systemic therapies and forecast overall survival.
ESTIMATING FUTURE NON-CULPRIT EVENTS WITH NEAR-INFRARED SPECTROSCOPY INTRAVASCULAR ULTRASOUND IMAGING: LIPID RICH PLAQUE STUDY SUB-ANALYSIS
Authors: Rebecca Torguson, Cheng Zhang, Paige Craig, Evan Shlofmitz, Hector Garcia Garcia, Ron Waksman
Journal: Journal of the American College of Cardiology (2020)
VALIDATION OF FULLY AUTOMATED DEEP LEARNING BASED ASSESSMENT OF LEFT VENTRICULAR EJECTION FRACTION FROM CARDIAC MAGNETIC RESONANCE IMAGES
Authors: Shuo Wang, Hena Patel, Keith Ameyaw, Miller Tamari, Akhil Narang, Keigo Kawaji, Victor Mor-Avi, Amit R. Patel
Journal: Journal of the American College of Cardiology (2020)
The international sinonasal microbiome study: A multicentre, multinational characterization of sinonasal bacterial ecology
Authors: Sathish Paramasivan, Ahmed Bassiouni, Arron Shiffer, Matthew R. Dillon, Emily K. Cope, Clare Cooksley, Mahnaz Ramezanpour, Sophia Moraitis, Mohammad Javed Ali, Benjamin Bleier, Claudio Callejas, Marjolein E. Cornet, Richard G. Douglas, Daniel Dutra, Christos Georgalas, Richard J. Harvey, Peter H. Hwang, Amber U. Luong, Rodney J. Schlosser, Pongsakorn Tantilipikorn, Marc A. Tewfik, Sarah Vreugde, Peter‐John Wormald, J. Gregory Caporaso, Alkis J. Psaltis
Journal: Allergy (2020)

Abstract The sinonasal microbiome remains poorly defined, with our current knowledge based on a few cohort studies whose findings are inconsistent. Furthermore, the variability of the sinus microbiome across geographical divides remains unexplored. We characterize the sinonasal microbiome and its geographical variations in both health and disease using 16S rRNA gene sequencing of 410 individuals from across the world. Although the sinus microbial ecology is highly variable between individuals, we identify a core microbiome comprised of Corynebacterium , Staphylococcus , Streptococcus , Haemophilus and Moraxella species in both healthy and chronic rhinosinusitis (CRS) cohorts. Corynebacterium (mean relative abundance = 44.02%) and Staphylococcus (mean relative abundance = 27.34%) appear particularly dominant in the majority of patients sampled. Amongst patients suffering from CRS with nasal polyps, a statistically significant reduction in relative abundance of Corynebacterium (40.29% vs 50.43%; P = .02) was identified. Despite some measured differences in microbiome composition and diversity between some of the participating centres in our cohort, these differences would not alter the general pattern of core organisms described. Nevertheless, atypical or unusual organisms reported in short‐read amplicon sequencing studies and that are not part of the core microbiome should be interpreted with caution. The delineation of the sinonasal microbiome and standardized methodology described within our study will enable further characterization and translational application of the sinus microbiota.
THE PROGNOSTING VALUE OF COMBING NEW BIOMARKERS FOR REMOTE CARDIOVASCULAR ENDPOINTS RISK STRATIFICATION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION
Authors: Naufal Zagidullin, Aysilu Hamitova, Lakman Irina, Krioni Ilja, Gareeva Diana, Zulkarneev Rustem, Tulbaev Eduard
Journal: Journal of the American College of Cardiology (2020)
IMPACT OF POLYVASCULAR DISEASE ON CLINICAL OUTCOME IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION
Authors: Masahiro Yamawaki, Motoharu Araki, Fumiaki Yashima, Hiroto Suzuyama, Hidetaka Nishina, Kazumasa Yamasaki, Masaki Izumo, Yoshifumi Nakajima, Yohei Ohno, Hiroshi Ueno, Kazuki Mizutani, Minoru Tabata, Akihiro Higashimori, Futoshi Yamanaka, Norio Tada, Kensuke Takagi, Toru Naganuma, Yusuke Watanabe, Shinichi Shirai, Masanori Yamamoto, Kentaro Hayashida
Journal: Journal of the American College of Cardiology (2020)
Vitamin E succinate induces apoptosis in pancreatic cancer cells
Authors: Dorrelyn Patacsil, Sylvester Osayi, Prafulla Gokhale, Mukesh Verma, Robert Clarke, Deepak Kumar
Journal: Cancer Research (2007)

19  Vitamin E Succinate (VES, α -tocopheryl succinate) is the most potent analog of Vitamin E that selectively induces apoptosis in cancer cells by modulating the expression of Bcl-2 family proteins. VES has been studied extensively as a chemopreventive, chemotherapeutic and chemosensitizing agent in various cancers types. However, there is limited data on the role of VES in pancreatic cancer. Pancreatic cancer is the number four cancer killer in the US and about 32,000 new cases are reported every year. The five year survival rate is only 5%. In this study, we investigated the effects of VES in three pancreatic cancer cell lines, COLO-357, PANC-1 and ASPC-1. We assessed the synergistic growth inhibitory effect of VES along with two known cytotoxic drugs, Etoposide and Gemcitabine. Cells were treated with varying concentrations (5 μM to 100 μM) of VES alone or in combination with Etoposide or Gemcitabine for different time periods. VES inhibited the cell proliferation of all the three pancreatic cancer cell lines in a time and dose dependant manner. Induction of apoptosis was evident in COLO-357 cells as determined by DNA fragmentation, PARP cleavage and increase in sub-G1 cells post treatment. We have also demonstrated that VES synergistically inhibits the cell growth in combination with 80 μM etoposide or 0.5 μg/ml Gemcitabine. In ASPC-1 cells, we also observed a dose dependent decrease in the expression of Bcl-XL in response to VES. This study demonstrates that (a)VES induces apoptosis in pancreatic cancer cell lines (b) VES synergistically inhibits the growth of pancreatic cancer cells in combination with cytotoxic drugs Etoposide or Gemcitabine and (c) VES down regulates the expression of antiapoptotic protein Bcl-XL in ASPC-1 cells.
Neurological outcomes of congenital Zika syndrome in toddlers and preschoolers: a case series
Authors: Heloisa Viscaino Fernandes Souza Pereira, Stella Pinto dos Santos, Ana Paula Rodrigues Lazzari Amâncio, Patricia Soares de Oliveira-Szejnfeld, Edneusa Oliveira Flor, Jousilene de Sales Tavares, Rayssa Vieira Brandão Ferreira, Fernanda Tovar-Moll, Melania Maria Ramos de Amorim, Adriana Melo
Journal: The Lancet Child & Adolescent Health (2020)
EVEROLIMUS-ELUTING XIENCE PRIME/X PEDITION VERSUS ZOTAROLIMUS-ELUTING RESOLUTE INTEGRITY STENTS IN PATIENTS WITH DIABETES MELLITUS AND SMALL VESSEL DISEASE: AN ANALYSIS FROM THE 2-YEAR PROSPECTIVE RANDOMIZED COPERES STUDY
Authors: Wonsik Yun, Yisik Kim, Sang-Rok Lee, Jei-Keon Chae, Ja-Yeon Lee
Journal: Journal of the American College of Cardiology (2020)
骨髄増殖性腫瘍(MPN)の症状評価フォーム全症状スコア: MPN患者における簡易症状負荷判定法の前向き国際評価
Authors: M Emanuel Robyn, C Dueck Amylou, L Geyer Holly, Kiladjian Jean-Jacques, Slot Stefanie, Zweegman Sonja, A W Te Boekhorst Peter, Commandeur Suzan, C Schouten Harry, Sackmann Federico, Fuentes Ana Kerguelen, Herndndez-Maraver Dolores, L Pahl Heike, Griesshammer Martin, Stegelmann Frank, Doehner Konstanze, Lehmann Thomas, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Harrison Claire, Radia Deepti, Muxi Pablo, Maldonado Norman, Besses Carlos, Cervantes Francisco, Johansson Peter, Barbui Tiziano, Barosi Giovanni, M Vannucchi Alessamdro, Passamonti Francesco, Andreasson Bjorn, Ferarri Maria, Rambaldi Alessandro
Journal: Journal of Clinical Oncology (2012)
Long-term follow-up of colorectal cancer (CRC) patients treated with neoadjuvant chemotherapy with irinotecan and fluorouracil plus folinic acid (5-FU/FA) for unresectable liver metastases
Authors: C. Pozzo, M. Basso, M. Quirino, G. Schinzari, A. Astone, N. Trigila, E. D’Argento, F. Sponziello, A. Cassano, C. Barone
Journal: Journal of Clinical Oncology (2006)

3576 Background: In a prospective study, neoadjuvant therapy with irinotecan and 5-FU/FA (modified FOLFIRI) enabled a significant proportion of CRC patients (pts) with initially unresectable liver metastases (LM) to undergo potentially curative surgical resection (Annals of Oncology 15:933–939, 2004). Here we report data on survival and time to progression (TTP) from long-term follow-up. Methods: Forty patients received irinotecan 180 mg/m 2 IV on day 1, FA 200 mg/m 2 IV on days 1 and 2, 5-FU IV bolus 400 mg/m 2 on days 1 and 2, and 5-FU 48-h continuous IV infusion 1200 mg/m 2 on day 1. Treatment was repeated every 2 wks, with response assessed every 12 wks (6 cycles), and continued until an objective response (OR), indicating suitability for surgery, disease progression, or unacceptable toxicity. Pts undergoing liver resection received a further 6 cycles postoperatively. Results: Nineteen (47.5%) of 40 pts had OR; 13 (33%) underwent resection. Treatment was well tolerated, with adverse events typical of agents used. As of June 30, 2005, median follow up was 30.4 months (mo). Median survival for all pts was 30.1 mo; median survival in nonresected pts was 24 mo, and overall survival (OS) in resected pts was not reached. TTP was 14.3 mo for all pts and 5.2 mo for nonresected pts. Disease-free (DF) survival in resected pts was 28.2 mo. Of resected pts, all were alive and 9 were DF at 1 y, all were alive and 6 were DF at 2 y, and 9 were alive and 6 DF at last follow-up. Conclusion: Surgical resection of LM after neoadjuvant treatment with modified FOLFIRI in CRC pts was followed by favorable DF and OS times. These data encourage use of irinotecan in pts with unresectable LM. Forthcoming studies should include arms with irinotecan-based combination regimens. [Table: see text]
Comparison between the common neoadjuvant regimens in locally advanced squamous cell cancer of oral cavity.
Authors: Rakesh Roy, Indranil Chatterjee, Indranil Chatterjee
Journal: Journal of Clinical Oncology (2013)

e17024 Background: In locally advanced squamous cell carcinoma of the oral cavity, neoadjuvant chemotherapy induces a high response rate that may facilitate definitive surgery or radiotherapy. Patients have an acceptable long-term survival.A strategy was developed in a tertiary care cancer hospital in India to treat patients with locally advanced oral cancers with induction CT followed by surgery if possible.In our centre selection of neoadjuvant regimens were based on following criteria: age, performance status, financial status, accessibility, comorbid illness, and lab parameters. Methods: 32 patients with locally advanced cancers of the oral cavity and inoperable upfront were selected for neoadjuvant chemotherapy. All were male patients, age ranging from 32 – 65 years, with a performance status ECOG 0-1. All had been tobacco users in some form and hailed from east and northeast parts of India. HPV data were unavailable. 2 patients had controlled diabetes. No other comorbidity was found. 20 patients got DCF (docetaxel, 5FU, cisplatin), 8 patients received PCF (paclitaxel, 5FU, cisplatin), 4 patients received PC (paclitaxel, carboplatin). 20-hr infusional 5FU daily was given over a period of 3 days in both the DCF and PCF arms unlike the 5 day infusion. All received growth factors as primary prophylaxis. Results: Patients who received DCF showed the best response followed by PCF and finally PC. Complete response (CR) was found in 6 patients, all of whom received DCF. All underwent surgery. Amongst toxicity neutropenia was highest with DCF arm but none developed febrile neutropenia. Patients exposed to 5FU had grade 1-2 diarrhoea in 90 % cases. No grade 3-4 mucositis were recorded. Diabetic patients who received PC and PCF and did not experience additional neurotoxicity. Dose reduction or modification was required in one patient who received DCF. Conclusions: Neoadjuvant chemotherapy is an useful treatment option for locally advanced cancers of the oral cavity. DCF regimen is most effective and well tolerated in Indian patients. Judicious selection of patient is necessary.
HEART FAILURE WITH PRESERVED EJECTION FRACTION IS COMMON AND DOES NOT PREDICT OUTCOMES IN LIVER TRANSPLANT RECIPIENTS
Authors: Milad C. El Hajj, James Fleming, Mona Haj, Apryl Cronley, Nicole Pilch, Ira Willner, Gregory Jackson, Derek DuBay, Brian Houston, Ryan James Tedford
Journal: Journal of the American College of Cardiology (2020)
ASSOCIATION BETWEEN HIGH-SENSITIVITY TROPONIN I AND MAJOR CARDIOVASCULAR EVENTS AFTER NON-CARDIAC SURGERY
Authors: Emmanuelle Duceppe, Flavia K. Borges, Maria Tiboni, Rupert Pearse, Matthew T.V. Chan, Sadeesh Srinathan, Peter Kavsak, David Szalay, Amit Garg, Daniel Sessler, Robert Sapsford, Shirley Pettit, Javiera Vasquez, P.J. Devereaux
Journal: Journal of the American College of Cardiology (2020)
Prospective study into the necessity of hemogram on day 8 in oral vinorelbine and cisplatin regimen.
Authors: Mariano Provencio, Antonio Sánchez, Manuel Domine, Angel Artal, Ramon Garcia-Gomez, Manuel Constenla, Jose Miguel Sanchez Torres, Javier Castro, Nuria Vinolas, Miriam Huelves, Javier Perez, Alfredo Sanchez-Hernandez
Journal: Journal of Clinical Oncology (2012)

e18011 Background: One of the standard treatments for metastatic non-small-cell lung cancer patients is the combination of cisplatin plus vinorelbine. This regimen is associated with a high rate of severe neutropenia, and a hemogram is therefore routinely performed on day 8 before the administration of vinorelbine. However, no prospective study has ever examined the rate of neutropenia detected in this hemogram or the rate of discontinuation of chemotherapy as a result. Since one of the objectives in the treatment of advanced lung cancer is to maintain quality of life, we performed this prospective study of cisplatin plus vinorelbine to address the question of whether this hemogram on day 8 could be avoided, thus eliminating unnecessary venipunctures without endangering patient safety. Methods: We included 58 chemotherapy-naïve advanced NSCLC patients from 10 centers. They received intravenous doses of cisplatin on day 1 plus oral vinorelbine on days 1 and 8, every 3 weeks, for a maximum of six cycles. Median age was 61 years; 87% were males; ECOG 1: 66%. Results: Of 189 cycles analyzed, vinorelbine was administered on day 8 in 661 (97.8%), and the dose was reduced or canceled in 15 (2.2%; IC 95%: 0.5 - 5.45) due to hematological toxicity. Conclusions: The hemogram on day 8 could potentially be avoided in patients ECOG 0-1 while still maintaining an acceptable safety margin.
EFFECTIVENESS AND SAFETY OF STANDARD AND REDUCED DOSES OF DABIGATRAN COMPARED TO RIVAROXABAN IN NONVALVULAR ATRIAL FIBRILLATION: LONG-TERM RESULTS FROM A COHORT STUDY IN THE FRENCH NATIONWIDE CLAIMS DATABASE
Authors: Nicholas Moore, Patrick Blin, Yves Cottin, Caroline Dureau-Pournin, Abdelilah Abouelfath, Régis Lassalle, Estelle Guiard, Aurélie Balestra, Patrick Mismetti, Gérard de Pouvourville, Jacques Bénichou, Cécile Droz-Perroteau
Journal: Journal of the American College of Cardiology (2020)
HSR20-107: Health-Related Quality of Life and Treatment Satisfaction in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Compared to a Reference Group on Other CLL Treatments in a Real-World US Cross-Sectional Study
Authors: Murali Sundaram, Kathleen L. Deering, Dolly Sharma, Qing Harshaw, Jeremiah Trudeau, Jacqueline C. Barrientos
Journal: Journal of the National Comprehensive Cancer Network (2020)

"HSR20-107: Health-Related Quality of Life and Treatment Satisfaction in Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib Compared to a Reference Group on Other CLL Treatments in a Real-World US Cross-Sectional Study" published on 20 Mar 2020 by National Comprehensive Cancer Network.
BASELINE RENAL DYSFUNCTION IS ASSOCIATED WITH INCREASED MORTALITY IN PATIENTS UNDERGOING PERCUTANEOUS MITRAL VALVE REPAIR: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Jakrin Kewcharoen, Chol Techorueangwiwat, Veraprapas Kittipibul, Chanavuth Kanitsoraphan, Thiratest Leesutipornchai, Sittinun Thangjui, Wasawat Vutthikraivit, Pattara Rattanawong, Dipanjan Banerjee
Journal: Journal of the American College of Cardiology (2020)
Non-dyadic wavelet decomposition for sensory-motor imagery EEG classification
Authors: Poonam Chaudhary, Rashmi Agrawal
Journal: Brain-Computer Interfaces (2020)

ABSTRACT Identification of imagined motor movement during cerebral activity is a significant task for translating the activity into control signals for brain–computer interface-based applications. This paper proposes a model based on non-dyadic wavelet decomposition for specifying left-hand and right-hand movement detection using motor imagery EEG signals. Three key components define our model: (1) The preprocessing and non-dyadic wavelet decomposition of EEG signals, (2) feature extraction using the common spatial pattern (CSP) coefficients of wavelet decomposed signals, (3) classification of test signal using selected features. The wavelet decomposition is done on the basis of m-band filtering. Classification of extracted features is done using different classifiers and obtained results are compared in terms of sensitivity, specificity, accuracy, and the kappa value. The proposed model gives the highest classification accuracy of 85.6% using decision tree classifier for BCI Competition 4 dataset IIa and BCI Competition 3 dataset IVa.
Effect of Acupuncture vs Sham Procedure on Chemotherapy-Induced Peripheral Neuropathy Symptoms
Authors: Ting Bao, Sujata Patil, Connie Chen, Iris W. Zhi, Qing S. Li, Lauren Piulson, Jun J. Mao
Journal: JAMA Network Open (2020)

to real acupuncture 24 Randomized to sham acupuncture
Whole genome sequencing to characterize luminal-type breast cancer.
Authors: Matthew James Ellis, Li Ding, Dong Shen, Jingqin Luo, Vera J. Suman, Reece J. Goiffon, John W. Wallis, Theodore C. Goldstein, Ken Chen, Donald Craig Allred, A. Marilyn Leitch, John A. Olson, David M. Ota, Mark Watson, David Piwnica-Worms, Ron Bose, Joshua M. Stuart, Richard K. Wilson, Kelly Hunt, Elaine Mardis
Journal: Journal of Clinical Oncology (2012)

503 Background: To correlate clinical features of estrogen receptor positive breast cancer with somatic mutations, massively parallel sequencing (MPS) was applied to tumor and normal DNAs accrued from patients treated with neoadjuvant aromatase inhibitors (AI). Methods: MPS was applied to 77 baseline tumor biopsy samples from the preoperative letrozole trial (JACS 2009: 208, 906) and the Z1031 trial (JCO 2011: 29, 2342) followed by targeted sequencing in another 240 trial samples. Standard statistical approaches were used to compare mutation status and clinical parameters and pathway-based correlation was used to assess interactions between signaling perturbations induced by gene mutations and response to neoadjuvant AI. Results: Eighteen genes were significantly mutated above background. Aside from PIK3CA mutations, the list is dominated by loss-of-function mutations in tumor suppressor genes. Five (RUNX1, CBFP, MYH9, MLL3 and SF3B1) have been previously linked to benign and malignant hematopoietic disorders. Clinical correlation revealed that TP53 mutation was associated with PAM50 LumB status, high-grade histology and high proliferation rates whereas loss-of-function mutations in MAP3K1 associate with PAM50 lumA status, low proliferation rates, and low grade histology. Mutations in GATA3 were associated with greater suppression of proliferation upon AI treatment suggesting mutGATA3 may predict endocrine response. Notably, mutations in MAP3K1 were more common in PIK3CA mutant cases, suggesting cooperation. Pathway analysis demonstrated that rare MAP2K4 mutations produce similar pathway perturbations as MAP3K1 mutation, a logical finding since MAP2K4 is a substrate for MAP3K1. Signaling network patterns driven by lncRNA MALAT1 mutations were associated with multiple poor clinical outcome features. Rare mutations in druggable kinases included two in the kinase domain of HER2. Conclusions: Tumor heterogeneity in luminal-type breast cancer is driven by specific patterns of somatic mutations, however most druggable or potentially prognostic mutations are infrequent. Prospective clinical trials based on these findings will require comprehensive genome sequencing approaches and large scale investigations.
POOR OUTCOMES ASSOCIATED WITH DIGOXIN DISCONTINUATION IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) MAY DIFFER BY BETA-BLOCKER USE
Authors: Ravi Masson, Awais Malik, Phillip Hong Lam, Hans Joseph Moore, Prakash Deedwania, Richard Allman, Steven Singh, Cherinne Arundel, Gregg C. Fonarow, Ali Ahmed
Journal: Journal of the American College of Cardiology (2020)
AORTIC VALVULAR DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA ADULT PATIENTS RECEIVING LDL APHERESIS
Authors: Yann Ancedy, Antonio Gallo, Stephane Ederhy, Saroumadi Adavane-Scheuble, Laurie Soulat-Dufour, Pascal Nhan, Marion Chauvet-Droit, Samir Saheb, Eric Bruckert, Ariel Cohen, Franck Boccara
Journal: Journal of the American College of Cardiology (2020)